ozanimod + itraconazole

This entry describes the **combination of ozanimod and itraconazole**. Ozanimod is a **small molecule sphingosine 1-phosphate receptor (S1P) modulator** used primarily for the treatment of relapsing multiple sclerosis and moderately to severely active ulcerative colitis. Ozanimod selectively binds S1P receptor subtypes 1 and 5, preventing lymphocytes from exiting lymphoid tissue, thus exerting immunomodulatory effects. Itraconazole is a **triazole antifungal agent** that inhibits ergosterol synthesis via inhibition of CYP51A1, affecting fungal cell membrane integrity. Itraconazole is also a strong inhibitor of CYP3A and P-glycoprotein (P-gp) in humans. Clinical pharmacokinetic studies show that concomitant administration of itraconazole with ozanimod causes a **minor increase (~13%) in the AUC (exposure) of ozanimod**, indicating a minor role of CYP3A and P-gp in ozanimod disposition[1][3]. No clinically relevant pharmacokinetic or pharmacodynamic interaction has been established between these drugs at standard dosing[1][3].

Other names

ozanimod + itraconazole